Sei sulla pagina 1di 132

Water for Pharmaceutical Use

WHO Technical Report Series


No 970, 2012. Annex 2

Water

Slide 1 of 25

2013

Supplementary Training Modules on


Good Manufacturing Practice
GMP Principle & Target AVOIDING
MIX UP & CROSS CONTAMINATION
GMP Approach
Systematic & SCIENTIFIC WAY &
RISK ASSESMENT with Patient Safety
Main Orientation
Water

Slide 2 of 25

2013

Water for Pharmaceutical Use


Objective
General principles, water system requirements and uses
Water quality specifications
Application of specific types of water to processes and dosage
forms
Water purification systems, storage and distribution
Operational considerations
Inspection of water systems
Water

Slide 3 of 25

2013

Water for Pharmaceutical Use


Introduction
Look at information on specifications of Water for
Pharmaceutical Use (WPU)
Which Quality of water to be used in production and control

APIs, finished products, etc.

GMP for design, installation, operation of systems


Supplementary to general GMP guidelines
See also other guidelines, pharmacopoeia, etc.
Water

Slide 4 of 25

2013

1.1.1 1.1.2

Water for Pharmaceutical Use


Additional guidelines
WHO Guideline for Drinking water quality (WHO)
Water and steam systems (ISPE)
Bioprocessing Equipment Standard (ASME BPE 2000)
European Pharmacopoeia, United States Pharmacopeia,
International Pharmacopoeia
Inspection of Utilities (PIC/S)
1.1.3

Water

Slide 5 of 25

2013

Water for Pharmaceutical Use


Principles
Like any starting material, production of water should conform to
Good Manufacturing Practice (GMP) norms
Potential for microbial growth
Systems must be properly validated / qualified
Water for parenteral use should not be contaminated with
pyrogens or endotoxins
Specifications and periodic sampling and testing required
Water

Slide 6 of 25

2013

Water for Pharmaceutical Use


Why purify raw water?
Although reasonably pure, it is always variable due to
seasonal variations, regional variation in water quality
Must remove impurities and control microbes to avoid
contaminating products
Treatment depends on waters chemistry and
contaminants, influenced by, e.g. rainfall, erosion,
pollution, dissolution, sedimentation, decomposition

Water

Slide 7 of 25

2013

Water for Pharmaceutical Use


Contaminants of water (1)
There is no pure water in nature, as it can contain up to 90
possible unacceptable contaminants
Contaminant groups:
Inorganic compounds
Organic compounds
Solids
Gases
Microorganisms

Water

Slide 8 of 25

2013

Water for Pharmaceutical Use


Contaminants of water (2)
Problem minerals
Calcium, magnesium, copper, aluminium, heavy metals,
arsenic, lead, cadmium, nitrates
Iron, manganese, silicates, carbon dioxide
Hydrogen sulfide
Phosphates
Water

Slide 9 of 25

2013

Water for Pharmaceutical Use


Contaminants of water (3)
Microorganisms Biofilm formation
Protozoa
Cryptosporidium
Giardia

Bacteria
Pseudomonas
Gram negative, non-fermenting bacteria
Escherichia coli and coliforms
Water

Slide 10 of 25

2013

Water for Pharmaceutical Use


Biofilm formation
1. Free-swimming aquatic bacteria use polymucosaccharides to
colonize surfaces
2. Complex communities evolve which shed
microcolonies and bacteria

Water

Slide 11 of 25

2013

Water for Pharmaceutical Use


Background to water requirements and use
Water is the most widely used substance / raw material
Used in production, processing, formulation, cleaning, quality
control
Unique chemical properties
Able to dissolve, absorb, adsorb, suspend compounds and
contaminants
Different grades of water quality available
See also EMEA "Note for guidance on the quality of water for
pharmaceutical use"
1.2.1

Water

Slide 12 of 25

2013

Water for Pharmaceutical Use


Background to water requirements and use (2)
Control quality of water during production, storage and

distribution

Contaminants, microbial and chemical quality


Microbial contamination risk and concern
Water is used on demand
not like other materials where sampled and tested, and THEN
used. Thus no batch or lot release before use. It has to meet the
specification "on demand" when used
1.2.2

Micro test results require incubation periods therefore results later


after already used
Water

Slide 13 of 25

2013

Water for Pharmaceutical Use


Background to water requirements and use (2)
Microbial control is a high priority
Microbes may proliferate (production, storage and
distribution)
System design, periodic sanitization and other
measures
Different grades of water quality (dependent
on its use)
1.2.3. 1.2.4.
Water

Slide 14 of 25

2013

Water for Pharmaceutical Use


General Principles of water systems
Design, installation, commissioning, qualification /
validation, operation, performance and maintenance to
ensure reliable, consistent production of water of required
quality
Prevent unacceptable microbial, chemical and physical
contamination during production, storage and distribution
Operate within design capacity
Quality Assurance involved in approval of use after
installation and maintenance work, or changes
Water

Slide 15 of 25

2013

2.1. 2.3.

Water for Pharmaceutical Use


Water system requirements (2)
Regular monitoring of:
Water quality
Chemical and microbiological
Endotoxin level where relevant

System performance, storage and distribution systems


Records of results, trends and action taken
Validated sanitization procedure followed on a routine basis

2.4. 2.5.

Water

Slide 16 of 25

2013

Water for Pharmaceutical Use


Water quality specifications
Presentation of water processed, stored and distributed in
bulk. (Not applicable for patient administration)
Specifications in pharmacopoeia include different types of
water
Drinking water / potable water
Bulk Purified water (BPW)
Bulk Highly Purified Water (BHPW)
Bulk Water for Injection (BWFI)
Water

Slide 17 of 25

2013

3.

Water for Pharmaceutical Use


Drinking water / potable water
Must comply with specification (WHO, ISO and national or
regional agencies) regular testing needed
Supplied under continuous positive pressure
Defect free plumbing system to prevent contamination
Could be from public water supply system or natural
sources
Source water quality influences the treatment required
3.2.1., 3.2.3.,
3.2.6.
Water

Slide 18 of 25

2013

Water for Pharmaceutical Use


Drinking water:
Natural sources could include
springs, wells, rivers and lakes
Treatment includes
desalinization, softening, removal
of specific ions, particle reduction
and antimicrobial treatment.

3.2.2

Water

Slide 19 of 25

2013

Water for Pharmaceutical Use


Bulk Purified Water (BPW)
Prepared from potable water (as minimum quality feed)
Meet pharmacopoeia specification - chemical and microbial
purity
Alert and action limits (determined)
Protected from recontamination
Protected from microbial proliferation
RO/EDI
Water

Slide 20 of 25

3.3.1.

2013

Water for Pharmaceutical Use


Bulk Highly Purified Water (BHPW)
Prepared from potable water (as minimum feed)
Specification only in the European Pharmacopoeia
Same quality standard as WFI (microbiological and limit for
endotoxins)
Prepared by combination of methods including double
reverse osmosis (RO) plus ultrafiltration (UF) and
deionization (DI)
Protect from recontamination and microbial proliferation

3.4.1. 3.4.3.

Water

Slide 21 of 25

2013

Water for Pharmaceutical Use


Bulk Water for Injections (BWFI)
Prepared from potable water source treated further, or PW
WFI is not sterile and is not a final dosage form
WFI is an intermediate bulk product
According to The International and European
Pharmacopoeias final purification step should be distillation
To meet pharmacopoeia specification for chemical and
microbial purity (including endotoxin)
Alert and action limits
Water

Slide 22 of 25

2013

3.5.1 3.5.4.

Water for Pharmaceutical Use


Application of specific types of water to
processes and dosage forms
Water used for different stages of:
Washing, preparation, synthesis, manufacturing, formulation

Which grade of water is suitable for a particular stage?


As required by national authority
Consider nature and intended use of intermediate or finished product
Stage in process where water is used

Let's look at types of water and indicate their use


4.1. 4.2.
Water

Slide 23 of 25

2013

Water for Pharmaceutical Use


Application of specific types of water to
processes and dosage forms
BHPW
preparation of products when water of high quality (i.e. very low in
microorganisms and endotoxins) is needed

BWFI
manufacture of injectable products for dissolving or diluting substances or
preparations during the manufacturing of parenterals
manufacture of sterile water for preparation of injections
final rinse after cleaning of equipment and components
preparation of steam

4.3. 4.5.

Water

Slide 24 of 25

2013

Water for Pharmaceutical Use


Complete the table
Use

Which type of water?

Preparation of injectable products

Final rinse of equipment after


cleaning

Final rinse of equipment and


components that come into
contact with injectable products

Water

Slide 25 of 25

HPW

Potable water
2013

Water for Pharmaceutical Use


Water purification systems: So far:
Principles for pharmaceutical water systems
Water quality specifications
Drinking-water, Bulk purified water, Bulk highly purified water, Bulk water for
injections

Specific types of water for processes and dosage forms


General considerations for water purification systems
Next slides focus on water purification, storage and distribution
systems
Water

Slide 26 of 25

2013

Supplementary Training Modules on


Good Manufacturing Practice
Water for
Pharmaceutical
Use
WHO Technical Report Series
No 970, 2012. Annex 2

Part 2
Water purification,
storage and
distribution
Water

Slide 27 of 25

2013

Water for Pharmaceutical Use


Objectives
To examine the basic technology and
requirements for:
Water purification systems
Storage and distribution requirements
Sanitization
5. - 6.

Water

Slide 28 of 25

2013

Water for Pharmaceutical Use


Water purification systems
Manufacturer to select appropriate method of purification
Appropriate sequence of purification steps
Influenced by, e.g.
Water quality specification
Feed water quality
Reliability and robustness of treatment system
Supplier support, maintenance and operation costs
5.1.1 5.1.2.

Water

Slide 29 of 25

2013

Water for Pharmaceutical Use


Water purification systems (2)
Influenced by, e.g.
the final water quality specification
the quantity of water required by the user
the available feed-water quality and the variation over time
(seasonal changes)
the availability of suitable support facilities for system
connection (raw water, electricity, heating steam, chilled water,
compressed air, sewage system, exhaust air)
5.1.1 5.1.2.

Water

Slide 30 of 25

2013

Water for Pharmaceutical Use


Water purification systems (3)
Influenced by, e.g. (cont.)

sanitization method
the reliability and robustness of the water-treatment equipment in
operation
the yield or efficiency of the purification system
the ability to adequately support and maintain the water
purification equipment
the continuity of operational usage considering hours/days, days/
years and planned downtime
5.1.1 5.1.2.
the total life-cycle costs
Water

Slide 31 of 25

2013

Water for Pharmaceutical Use


Water purification system considerations:
Location of the plant room; temperatures
Leachates and adsorptive contact materials
Hygienic or sanitary design
Corrosion; leakage
Proliferation of microbiological organisms, cleaning; sanitizing
Capacity and output requirements
Instruments, test and sampling points
Water

Slide 32 of 25

2013

5.1.3

Water for Pharmaceutical Use


Water purification system considerations (2)
Physical considerations:
Ability to collect samples
Space available for the installation
Structural loadings on buildings
Adequate access for maintenance
Regeneration and sanitization chemicals.
5.1.4

Water

Slide 33 of 25

2013

Water for Pharmaceutical Use


Pre-treatment steps
Primary filtration and multimedia filter
Coagulation or flocculation
Desalination
Softening

Water

Slide 34 of 25

2013

Water for Pharmaceutical Use


Pretreatment
schematic
drawing

float
operated
valve

excess water recycled


from deioniser
air filter

sand filter

spray ball

Water is kept
circulating

raw water in

centrifugal pump

S trap to sewer
|

Slide 35 of 25

2013

To water
softener &
DI plant

break tank

air break to drain

Water

activated
carbon
filter

cartridge
filter
5 micrometers

Water for Pharmaceutical Use


Water pre-treatment
complex in a pretreatment room

Water

Slide 36 of 25

2013

Water for Pharmaceutical Use


Water Softener schematic drawing
by pass valve

"soft" water to deioniser

brine and salt tank

brine

"hard" water
in

drain
Water

Slide 37 of 25

2013

zeolite water softener


-exchanges
-Ca and Mg for Na

Water for Pharmaceutical Use


Chlorine removal (Activated-carbon (AC)
filtration or bisulphite)
AC removes chlorine but bacteria can then grow
AC filtration can remove organic impurities
Bisulphite leaves sulphate residues but is antimicrobial

Water

Slide 38 of 25

2013

Water for Pharmaceutical Use


Production of drinking water
Derived from raw water source (e.g. well, river, reservoir)
Processes may include:
desalinization; filtration
softening; disinfection or sanitization (e.g. by sodium hypochlorite
(chlorine) injection)
iron (ferrous) removal
precipitation
reduction of concentration of specific inorganic and/or organic
materials
5.2.1 5.1.2.
Water

Slide 39 of 25

2013

Water for Pharmaceutical Use


Drinking water (2)
Routine monitoring of quality cover environmental, seasonal or
supply changes
Additional testing when change in the raw water source,
treatment techniques or system configuration
Trend review
When quality changes significantly, but is still within specification, the direct
use as a WPU, or as the feed-water to downstream treatment stages,
should be reviewed and the result of the review documented
5.2.3. 5.2.5.
Water

Slide 40 of 25

2013

Water for Pharmaceutical Use


Drinking water (3)
Producing drinking water through an "in-house" system
requires well documented system configuration and water
quality monitoring
Change control approved by QA
Storage of water:
no degradation, ensure turnover, routine testing
"indirect impact system" qualification not needed
Water

Slide 41 of 25

2013

5.2.6. 5.2.8.

Water for Pharmaceutical Use


Drinking water (4)
System design allows for draining and sanitization
Closed storage tanks:
With protected vents
Allows for visual inspection
Draining and sanitization possible (also pipework)

Control microbiological contamination of sand filters, carbon


beds, water softeners. Measures include:
5.2.10. 5.2.11.
back-flushing, chemical or thermal sanitization and frequent
regeneration, continuous waterflow
Water

Slide 42 of 25

2013

Water for Pharmaceutical Use


Drinking water (5)
When supplied in bulk or by tanker identify problems and
risks
Risk control:
Vendor assessment
Authorized certification activities
Acceptability of delivery vehicle

Similar as other starting materials


5.2.9.
Water

Slide 43 of 25

2013

Water for Pharmaceutical Use


Production of Purified Water (PW) (1)

Slide 44 of 25

2013

raw water

drain or recycle

Purified water

Permeate
water

Water

under
pressure

Reject
water

Includes: Ion exchange,


Reverse Osmosis,
Ultrafiltration and/or
EDI and distillation

Feed
water

Semi-permeable
membrane

Use appropriate, qualified


methods to produce PW.

Low pressure

High pressure

5.3.1.

Water for Pharmaceutical Use


Factors to consider in URS for PW:
feed-water quality (and variation over seasons) and waterquality specification;
quantity of water required;
sequence of purification stages and energy consumption;
extent of pretreatment needed;
performance optimization;
appropriately located sampling points;
appropriate instrumentation to measure parameters such as
flow, pressure, temperature, conductivity, pH and total organic
carbon.
5.3.2.
Water

Slide 45 of 25

2013

Water for Pharmaceutical Use


Production of Purified Water (2)
Ambient temperature PW systems are susceptible to
microbiological contamination especially when static and
periods of low or no demand
Evidence of effective controls
Sanitization at different stages of purification
If agents are used proof of removal

5.3.3
Water

Slide 46 of 25

2013

Water for Pharmaceutical Use


Production of Purified Water (3)
Controls may include:
Maintain minimum flow at all times
Control temperature in the system e.g. < 25 C
Provide ultraviolet disinfection
Use components that can periodically be thermally sanitized
Chemical sanitization (e.g. ozone, hydrogen peroxide and/or
peracetic acid) and thermal sanitization at > 70 C
5.3.4.
Water

Slide 47 of 25

2013

Water for Pharmaceutical Use


Production of Highly Purified Water (HPW)
Produced by double-pass reverse osmosis coupled with
ultrafiltration or by any other appropriate qualified purification
technique or sequence of techniques.
Same principles as for Purified Water

5.4.1. 5.4.2
Water

Slide 48 of 25

2013

Water for Pharmaceutical Use


Typical 2-stage RO schematic
Water from softener or de-ioniser

Second stage reject water goes back to first stage buffer tank
1st stage reject concentrate

1st stage buffer tank

First stage RO cartridge

Branch

Branch

First stage filtrate feeds second stage RO


. excess back to 1st stage buffer tank
with
Air break
to sewer

2nd stage buffer tank

Second stage RO cartridge

High pressure
pump
Second stage RO water
meets Pharmacopoeia
standards

Water

Slide 49 of 25

2013

Cartridge
filter 1 m

Hygienic pump

Water returns to 1st stage buffer tank


Outlets or storage

Water for Pharmaceutical Use


Production of Water for Injections (WFI)
Distillation is preferred technique also in some Pharmacopoeia
Factors to consider in design:
Feed water quality
Required water quality specification and quantity of water
Optimum generator (size and variable control to prevent
frequent start/stop)
Blow-down and dump functions
Cool-down venting (to avoid contamination ingress)
Similar principles as for PW
Water

Slide 50 of 25

2013

5.5.1. 5.5.3

Water for Pharmaceutical Use


Water storage and distribution systems
This section applies to WPU systems for PW,
BHPW and BWFI
The water storage and distribution to work in
conjunction with the purification plant to ensure
delivery of water of consistent quality to the user
points, and to ensure optimum operation of the
water purification equipment
6
Water

Slide 51 of 25

2013

Water for Pharmaceutical Use

What are the


main
components
in a water
storage and
distribution
?system
6.

Water

Slide 52 of 25

2013

Water for Pharmaceutical Use


Typical water storage and distribution schematic
Hydrophobic air filter
& burst disc

Feed Water
from
DI or RO

Cartridge
filter 1 m

Water must
be kept
circulating

Spray ball

Optional
in-line filter
0,2 m
UV light
Outlets

Heat Exchanger
Ozone Generator
Water

Slide 53 of 25

2013

Hygienic pump

Air break
to drain

Water for Pharmaceutical Use


General
PW usually stored in a vessel for subsequent use
Storage and distribution system is a key part of the whole system
Should be appropriately designed
Configured to prevent microbial proliferation and recontamination of
the water (PW, BHPW, BWFI) after treatment
Online and offline monitoring to ensure that the appropriate water
specification is maintained
6.1.1. 6.1.3

Water

Slide 54 of 25

2013

Water for Pharmaceutical Use


Contact materials
Materials that come into contact with WPU should
be appropriate
Includes:

Water

pipework
valves and fittings
seals
diaphragms and
Instruments

Slide 55 of 25

2013

6.2.1. 6.2.2.

Water for Pharmaceutical Use


Contact materials Considerations (1)
Compatibility

Prevention of leaching
Corrosion resistance
Smooth internal finishing
Jointing
Unions and valves
Water

Slide 56 of 25

2013

6.2.2.

Water for Pharmaceutical Use


Contact materials Considerations (2)
Compatibility
Temperature and chemicals, operation, rest and sanitization

Prevention of leaching
Non leaching operation and sanitization

Corrosion resistance
SS316L, cleaning and passivation

Smooth internal finishing


Water

Slide 57 of 25

2013

6.2

Water for Pharmaceutical Use


Contact materials Considerations (3)
Jointing
Smooth. Controls (welder qualification, set-up, work session
test pieces, logs, visual inspection reports

Unions and valves


Sanitary design (no threads)

Materials
E.g. SS316L, polypropylene, PVDF
Water

Slide 58 of 25

2013

6.2

Water for Pharmaceutical Use


System sanitization and bioburden control
Systems in place to control proliferation of microbes
Techniques for sanitizing or sterilization
Consideration already during design stage suitable
materials of construction.
Validated procedure
Special precautions if water not kept > 65 degrees Celsius
6.3.1. -.6.3.2.

Water

Slide 59 of 25

2013

Water for Pharmaceutical Use


Storage Vessel requirements
Design and size important
Capacity
Buffer capacity (generation and use); operate continuously,
avoid inefficiencies due to frequent on and off cycles
Sufficient for short-term reserve in case of failure
Contamination control consideration
Headspace (kept wet with spray ball / distributor device)
Nozzles (no dead zone design)
6.4.3
Vent filters (type, testing, use of heat)
Pressure relief valves and burst discs (sanitary design)
Water

Slide 60 of 25

2013

Water for Pharmaceutical Use

Storage Vessel
Considerations
and
components

Water

Slide 61 of 25

2013

Water for Pharmaceutical Use


Requirements for water distribution pipework
General considerations
Temperature control
Circulation pumps
Biocontamination control techniques
6.5.

Water

Slide 62 of 25

2013

Water for Pharmaceutical Use


General considerations
Continuous circulating loop
Control proliferation of contaminants
No filters in loops or at user points
Circulation pumps sanitary design
Stand by no stagnant water
6.5.1.1. 6.5.1.2.; 6.5.3.
Water

Slide 63 of 25

2013

Water for Pharmaceutical Use


Temperature control
Heat exchangers should not be source of
contamination
Double tube plate or double plate and frame or tube and shell
configuration preferred
arranged in continually circulating loops or sub-loops to avoid
static water
Where cooling is done for minimum periods of time

6.5.2.1. 6.5.2.3., 6.5.3


Water

Slide 64 of 25

2013

Water for Pharmaceutical Use


Biocontamination control techniques
Sanitization (chemical or thermal) - production
and distribution and include:
Continuous turbulent flow circulation
Shortest possible length of pipework
Isolated from adjacent hot pipes
6.5.4..2
Water

Slide 65 of 25

2013

Water for Pharmaceutical Use


Biocontamination control techniques (2)
Minimized deadlegs

(NMT 3D)

Pressure gauges separated


by membranes
Use of diaphragm valves
Sloped and fully drainable
Water

Slide 66 of 25

2013

6.5.4.2

Water for Pharmaceutical Use

Water

Slide 67 of 25

2013

Water for Pharmaceutical Use


What type of valves
?are these

Water

Slide 68 of 25

2013

Water for Pharmaceutical Use


Biocontamination control techniques (2)
There should be no dead legs
D
Flow direction arrows
on pipes are important

Dead leg:
Measured from the ID pipe
wall to centre line of the
point-of-use valve where
significant stagnation
potential exists
Water

Slide 69 of 25

2013

Dead leg section

Sanitary Valve
Water scours dead leg

Water for Pharmaceutical Use


The growth of microorganisms can be inhibited by:
UV radiation
Maintain system <25C or > 65C
Periodic and routine sanitizing of the system e.g.
with:
water > 70 C)
superheated hot water or clean steam
chemicals e.g. ozone
Water

Slide 70 of 25

2013

6.5.4.2.

Supplementary Training Modules on


Good Manufacturing Practice
Water for
Pharmaceutical
Use
Part 3:
Operational
considerations
WHO Technical Report Series
No 970, 2012. Annex 2
Water

Slide 71 of 25

2013

Water for Pharmaceutical Use


Objective of this part is to discuss the
operational considerations of water systems
including:
Start up and commissioning
Qualification and validation
Continuous system monitoring
Maintenance
Water system review
Water

Slide 72 of 25

2013

7.

Water for Pharmaceutical Use


Commissioning
Planned, well defined, well documented commissioning can
help to ensure appropriate qualification and validation
Includes
setting to work and system set-up
controls and loop tuning
System performance parameters

If commissioning is part of qualification then appropriate


7.1
level of documentation and compliance with VMP
Water

Slide 73 of 25

2013

Water for Pharmaceutical Use


Qualification
WPU, BPW, BHPW, BWFI are "direct impact, quality critical
systems
Should be qualified and be subjected to DQ, IQ, OQ, PQ
DQ: Design review influenced by source water and required
water quality
IQ: Installation verification of the system
OQ: operational qualification
Water

Slide 74 of 25

2013

7.2

Water for Pharmaceutical Use


Qualification (2)
This presentation will focus on PQ
PQ demonstrates consistent and reliable performance of the
system

Three phase approach - over extended period


Proves reliability and robustness
Include tests on source water (drinking water quality)
7.2
Water

Slide 75 of 25

2013

Water for Pharmaceutical Use


Phase 1.
Daily sampling (or continuously monitor) of incoming feed-water
Cover two weeks of intensive monitoring
System should operate continuously without failure or
performance deviation
Water is not used for finished pharmaceutical product (FPP)
manufacturing during this period

7.2
Water

Slide 76 of 25

2013

Water for Pharmaceutical Use


The testing approach in Phase I:
Chemical and microbiological testing follow a defined plan
Include incoming feed-water daily to verify its quality
After each step in the purification process
Each point of use and at other defined sample points
Develop appropriate operating ranges
Develop and finalize operating, cleaning, sanitizing and
maintenance procedures
Water

Slide 77 of 25

2013

7.2

Water for Pharmaceutical Use


The testing approach in Phase I:
Demonstrate product water of the required quality and quantity
Use and refine SOPs (operation, maintenance, sanitization and
troubleshooting)
Verify provisional alert levels
Develop and refine test-failure procedure

7.2
Water

Slide 78 of 25

2013

Water for Pharmaceutical Use


Phase 2.
Follows Phase 1 further two week test period with intensive
monitoring using refined SOPs
Sampling scheme generally the same as in phase 1
May use water if commissioning and Phase 1 data okay
Phase 2 to show:
consistent operation within established ranges;

consistent production and delivery of water of the required


quantity and quality when the system is operated in accordance
7.2
with the SOPs
Water

Slide 79 of 25

2013

Water for Pharmaceutical Use


Phase 3.
Normally over one year after the satisfactory completion of phase 2
Water can be used for FFP manufacturing
Objectives of phase 3 include
to demonstrate reliable performance over an extended period
to ensure that seasonal variations are evaluated

The sample locations, sampling frequencies and tests should be


reduced to the normal routine pattern based on established
procedures proven during phases 1 and 2
7.2
Water

Slide 80 of 25

2013

Water for Pharmaceutical Use


Continuous system monitoring
After completion of phase 3 do a system review
Then implement a routine monitoring plan (based on results from
phase 3)
A combination of on-line monitoring and off-line sample testing
with qualified alarm systems
Verify that the water met the pharmacopoeia and in house
specification
7.3.1. 7.3.2.
Water

Slide 81 of 25

2013

Water for Pharmaceutical Use


Continuous system monitoring (2)
Parameters to be monitored include:
flow, pressure, temperature, conductivity and total organic carbon,
physical, chemical and microbiological attributes

Offline samples taken from points of use or dedicated sample


points (where points of use cannot be sampled)
Water samples to be taken in the same way as when water is
taken for use in production. (A suitable flushing and drainage
procedure followed)
Data analysed for trends RCA and CAPA
Water

Slide 82 of 25

2013

7.3.1. 7.3.3.

Water for Pharmaceutical Use


Maintenance
A controlled, documented maintenance programme covering:
Defined frequency for system elements; a calibration programme
SOPs for tasks; control of approved spares
Maintenance plan and instructions
Review and approval of systems for use upon completion of work
Record and review of problems and faults during maintenance
7.4
Water

Slide 83 of 25

2013

Water for Pharmaceutical Use


System reviews
Regular intervals by a team (from engineering, QA, microbiology,
operations and maintenance) and cover:

Water

changes made since the last review


system performance
reliability
quality trends
failure events
investigations
out-of-specifications results from monitoring
changes to the installation
updated installation documentation
log books and status of the current SOP list

Slide 84 of 25

2013

7.5.1.

Water for Pharmaceutical Use


System reviews (2)
For new / instable / unreliable systems, also review:
The need for investigation
Corrective actions and preventative actions (CAPA)
Qualification (DQ, factory acceptance test (FAT), IQ, site
acceptance test (SAT), OQ, PQ) or equivalent verification
documents
The monitoring phases of the system
7.5.2.
Water

Slide 85 of 25

2013

Water for Pharmaceutical Use


Summary
In Parts 1, 2 and 3 we looked at:
Water requirements and uses
general principles for pharmaceutical water systems
water quality specifications
application of specific types of water to processes and dosage forms

Water purification systems


Water storage and distribution systems
Operational considerations

In Part 4 discuss approaches to inspection of water systems


Water

Slide 86 of 25

2013

Supplementary Training Modules on


Good Manufacturing Practice
Part 4:

Inspection of water
purification systems
WHO Technical Report Series
No 970, 2012. Annex 2
Water

Slide 87 of 25

2013

Supplementary Training Modules on


Good Manufacturing Practice

I start with:

As much as I learn, as
much as I dont know
Water

Slide 88 of 25

2013

Supplementary Training Modules on


Good Manufacturing Practice
The Angle point of This Training session :

cGMP Compliance, QA &


Inspector Perspective for Water
System
instead of Technical Construction
perspective
Water

Slide 89 of 25

2013

Supplementary Training Modules on


Good Manufacturing Practice
GMP Principle & Target AVOIDING
MIX UP & CROSS CONTAMINATION
GMP Approach
Systematic & SCIENTIFIC Based &
RISK ASSESMENT with Patient Safety
Main Orientation
Water

Slide 90 of 25

2013

Supplementary Training Modules on


Good Manufacturing Practice
Chapter 4
Pretreatment
Options

Chapter 1
Introducti
on

Water

Chapter 2
Key Design
Philosophi
es

Slide 91 of 25

2013

Chapter 3
Water
Options and
System
Planning

Chapter 5
Final
Treatment
Options: NonCompendial &
Compendial
Purified
Water
Chapter 6
Final
Treatment
Options:
Water For
Injection
(WFI) 7
Chapter
Pharmaceutic
al Steam

Chapter 8
Storage and
Distribution
Systems
Chapter 9
Instrumentati
on & Control
Chapter 10
Commissionin
g and
Qualification
Chapter 11
Appendix

Key Design & Philosophies


Introduction
To understand:
The nature of producing pharmaceutical water is to minimize or
eliminate potential source of contamination
It must be demontrated tahat all pharmaceutical waters (noncompendial US Pharmacopeia (USP) monograph compendial
waters) can be produced consistenly to spesification
USP covers 2 compedial water qualities (USP PW and USP
WFI) and non compendial water
Water

Slide 92 of 25

2013

Key Design & Philosophies


Introduction
To understand:
The nature of producing pharmaceutical water is to minimize or
eliminate potential source of contamination
It must be demontrated tahat all pharmaceutical waters (noncompendial US Pharmacopeia (USP) monograph compendial
waters) can be produced consistenly to spesification
USP covers 2 compedial water qualities (USP PW and USP
WFI) and non compendial water
Water

Slide 93 of 25

2013

Water for Pharmaceutical Use


CPP
To understand:
Critical parameters are defined as those parameters that directly affect the
product Quality.
Ex: since microbial quality cannot be diretly monitored in real time, the
parameters relied upon to control microbial growth are normally considered
as CRITICAL. These may include temp, UV intensity, ozone concentration,
circulating system under positive pressure, etc. The rest compendial water
properties mandated in the official monograph obviously constitute critical
parameters
Water system inspection techniques and approaches
Water

Slide 94 of 25

2013

Water for Pharmaceutical Use

Water

Slide 95 of 25

2013

Water for Pharmaceutical Use


Objectives
To understand:
The specific requirements when inspecting water systems,
including associated documentation
Water system inspection techniques and approaches

Water

Slide 96 of 25

2013

Water for Pharmaceutical Use


Prepare an aide-memoire for items to inspect (1)
May include:
Schematic drawing review
Changes to system since installation
Sampling procedure and plan
Specifications, results and trends
Out-of-specification results
Annual system review
Deviations

Water

Slide 97 of 25

8.

2013

Water for Pharmaceutical Use


Prepare an aide-memoire for items to inspect (2)
Results of system performance monitoring
Out of limit results, failure investigations and alarms recorded
Sanitization procedures and records
Maintenance and repairs logs/records
Instrument calibration and standardization
Qualification and validation including DQ, IQ, OQ, PQ
Requalification when appropriate, etc.
8.

Water

Slide 98 of 25

2013

Water for Pharmaceutical Use


Where to start:
What is the water to be used for?
sterile products
non-sterile products, e.g. oral liquid products, external
applications
solid dosage forms
washing and rinsing
Start: Document review site verification followed by additional
document review

Water

Slide 99 of 25

2013

Water for Pharmaceutical Use


Verification:
Start with document review (e.g. schematic drawing of the
system, "water quality manual" if available, system review)
Review qualification reports, then change controls (in case of
changes and requalification if appropriate)
Do on site verification (system in accordance with the drawings,
no leaks, calibration etc.)
Start with source water supply
Then pre-treatment and treatment systems
Water

Slide 100 of 25

2013

Water for Pharmaceutical Use


Documentation should reflect information on: (1)
Pipeline
Valves (non-return type)
Breather points
Couplings
Pipe slope
Velocities
Sampling points
Drain points
Instrumentation
Flow rates

Water

Slide 101 of 25

2013

Water for Pharmaceutical Use


Documentation should reflect information on: (2)
Specification for each system element
Standard procedures for use
System changes
Routine and non-routine maintenance
Investigations and corrective action
Validation studies
Chemical and microbiological specifications
Sampling instructions
Test procedures
Responsible persons
Training requirements
Water

Slide 102 of 25

2013

Water for Pharmaceutical Use


On site review and verification for raw water
Storage may be required prior to pre-treatment
Check material of construction of tank
Concrete, steel are acceptable but check corrosion
Plastics or plastic linings may leach

Check the suitability of the cover


To keep out insects, birds and animals

Check disinfection practices

Water

Slide 103 of 25

2013

Water for Pharmaceutical Use


On site review and verification (e.g. PW):
Start with source water supply follow whole system "loop"
Walk through the system, verifying the parts of the system
as indicated in the drawing
Review SOPs "on site" with the relevant records, logs,
results
Verify components, sensors, instruments
Inspect the finishing, state, calibration status, labels, pipes,
tanks etc as discussed in previous parts of this module
Water

Slide 104 of 25

2013

Water for Pharmaceutical Use


Water treatment system inspection (1)
Checks may include:

Water

dead legs
filters
pipes and fittings
Ionic beds
storage tanks
by-pass lines

Slide 105 of 25

2013

Water for Pharmaceutical Use


Water treatment system inspection (2)
Checks may include:

Water

pumps
UV lights
sample points
reverse osmosis
valves
heat exchangers
Instruments, controls, gauges, etc.

Slide 106 of 25

2013

Water for Pharmaceutical Use


Other checks (1)
Material of construction
Weld quality
Hygienic couplings
Passivation procedure and records
Air breaks or Tundish

Water

Slide 107 of 25

2013

Water for Pharmaceutical Use


Other checks (2)
Pipes and pumps
hygienic couplings
welded pipes
hygienic pumps
hygienic
sampling points
acceptable floor
no leaks

Water

Slide 108 of 25

2013

Water for Pharmaceutical Use


Other checks (3)
Check condition of equipment

Staining on
water storage
tanks

Corrosion on plates of heat exchangers


indicates possible contamination
Water

Slide 109 of 25

2013

Water for Pharmaceutical Use


Other checks (4)
Maintenance records, maintenance of pump seals and O rings

Water

Slide 110 of 25

2013

Water for Pharmaceutical Use


Other checks (5)
Air filters
Integrity

testing

Sterilization

and replacement

frequency
Check

Water

burst discs

Slide 111 of 25

2013

Water for Pharmaceutical Use


Other checks (6)
Temperature-compensated conductivity meters
Influence of plastic pipe adhesive on TOC
Non-condensable gases in pure steam

Water

Slide 112 of 25

2013

Water for Pharmaceutical Use


Other checks (7)
UV light monitoring performance and lamp life and
intensity
Validating ozone dosage
Specifications for acids, alkalis for DI and sodium chloride
for water softener
Normally open and normally closed valves
Water

Slide 113 of 25

2013

Water for Pharmaceutical Use


Documentation review may include:
Qualification protocols and reports
System review
Change control request (where applicable)
Requalification (where applicable)
QC and microbiology test results and trends, OOS and OOT
Procedures and records
Water

Slide 114 of 25

2013

Water for Pharmaceutical Use


Sampling (1)
Review the sampling procedure (SOP) with a sampling plan
(user and sampling points)
Sample integrity must be assured
Sampler training
Sampling point , sample size, sample container and label
Sample transport and storage
When is the test started?
Test method is the filtration method used? Which media?
Water

Slide 115 of 25

2013

Water for Pharmaceutical Use


Sampling (2)
Verify compliance with the procedure and plan
Ensure that samples were taken and not skipped
Review trends
Alert and action limits, 2 sigma

OOS, OOL, OOT results


Investigations and CAPA

Water

Slide 116 of 25

2013

Water for Pharmaceutical Use


Testing
Review method verification
Chemical testing
Microbiological testing
test method
types of media used preferred R2A
How was the media sterilized validated procedure
incubation time and temperature
objectionable and indicator organisms
Manufacturers specifications
Water

Slide 117 of 25

2013

Water for Pharmaceutical Use


Suggested bacterial limits (CFU /mL)
See Pharmacopoeia
Sampling location

Target

200

Alert

Action

300

500

Post multimedia filter

100

300

500

Post softener

100

300

500

Post activated carbon


filter
Feed to RO

50

300

500

20

200

500

RO permeate

10

50

100

Points of Use

10

100

Raw water

Water

Slide 118 of 25

2013

Water for Pharmaceutical Use


Pyrogens and endotoxins
Where required, verify testing for pyrogens and endotoxins
Pyrogen : When injected into mammals will give rise to fever
Endotoxins are pyrogenic, come from Gram negative bacterial cell
wall fragments
Detect endotoxins using a test for lipo-poly-saccharides (LPS)
rabbit test detects pyrogens
LAL test detects endotoxins
Ultra-filtration, distillation and RO may remove pyrogens
Water

Slide 119 of 25

2013

Water for Pharmaceutical Use


Group Session
You are given a schematic drawing of a water system to discuss. List any
problems you identify and discuss their solutions

IN C O R R E C T W A T E R T R E A T M E N T PL A N T
Water

Slide 120 of 25

2013

Water for Pharmaceutical Use


Group Session

M O D IF IE D W A T E R T R E A T M E N T PL A N T
Water

Slide 121 of 25

2013

Water for Pharmaceutical Use


Group Session

Water

1.

Integrity test for vent filter of PW storage tanks and WFI storage tanks have been done
(total 4 storage tanks), but it can not be ensured the link and match of the filter integrity
report against the filter/housing filter itself. No ID filter/housing on integrity report

2.

Vent filter handling is stated on doc SOP ENG-UT/MSO/LS/032, It is not mentioned whether the
integrity tested filter (with pass integrity test status) will be re-used for the next certain period or
replaced with the new one.
If it is prolong used, the cycle of usage should be identified, controlled, justified and documented

3.

Integrity test of vent filter is executed for every 6 months, last testing was June 2014.
There is no test integrity record for Jan 2014 (the previous 6 month prior to June 14)

4.

Integrity test report of vent filter is complied with singles page. It is not attached in proper form,
so the potential to page missing.
There is no approval from checker, just approved by single operator. Double approved Quality
team (QA) is really recommended since this is product quality direct impact

Slide 122 of 25

2013

Water for Pharmaceutical Use


Group Session
5.

Observation on Raw water plant


There is no marking of acceptance criteria pressure Magnehelic
Some marking of water direction flow is missing and half was blur

6.

The monitoring time for recording 10 micron filter in DRW installation is not mentioned. SOP ENG15/MSO/LS/026

7.

8.

Water

Documentation of Monitoring system of DRW filter is not equipped by acceptance criteria so that
operator know whether it is meet spec or OOS.
Marking of acceptance criteria pressure on Magnehelic is not in place
Some piping direction was found in Blur condition, can not see clearly

The pressure monitoring of DRW Filter 08/DRW-F-234 was OUT OF ORDER STATUS. Out of order
label was in place, but its filtration system was still used for filtering process as feed water to PW
generator

Slide 123 of 25

2013

Water for Pharmaceutical Use


Group Session
Log book filter monitoring ENG-UT/FOR/086 are equipped with star marking. The issue was
happen on recurrences mode from 1-20 Oct 2014. On that issue, there is no documented
investigation for closing the issue

10.

Alert limit of conductivity on PW generator has not yet established


The control data just using action limit only.

11.

Alert limit or action limit of PW quality (etc: conductivity) is not conected to proper sound/light alarm to
Room supervisor or out side area of water system room

12.

All calibration labels including probe sensor, display, pressure transmitter, temperature sensor of PW
Generator/Christ Osmotron are over due

13.

Challenge of password level authorization on PW Generator Osmotron was done during observation. It
didnt represent any pass world level in place. All people during inspection can enter osmotron PLC
system using the same password. While the SOP has already been available

14.

SOP of cool loop sanitation has been available, defined frequency is every 3 months using Hydrogen
peroxide.
The record of the last 3 months has not yet shown to the auditor.
The evidence of residual H2O2 is not documented

Water

Slide 124 of 25

2013

Water for Pharmaceutical Use


Group Session
Log book filter monitoring ENG-UT/FOR/086 are equipped with star marking. The issue was
happen on recurrences mode from 1-20 Oct 2014. On that issue, there is no documented
investigation for closing the issue

10.

Alert limit of conductivity on PW generator has not yet established


The control data just using action limit only.

11.

Alert limit or action limit of PW quality (etc: conductivity) is not conected to proper sound/light alarm to
Room supervisor or out side area of water system room

12.

All calibration labels including probe sensor, display, pressure transmitter, temperature sensor of PW
Generator/Christ Osmotron are over due

13.

Challenge of password level authorization on PW Generator Osmotron was done during observation. It
didnt represent any pass world level in place. All people during inspection can enter osmotron PLC
system using the same password. While the SOP has already been available

14.

SOP of cool loop sanitation has been available, defined frequency is every 3 months using Hydrogen
peroxide.
The record of the last 3 months has not yet shown to the auditor.
The evidence of residual H2O2 is not documented

Water

Slide 125 of 25

2013

Water for Pharmaceutical Use


Group Session

Water

15.

Label of Out of Order is not using registered label

16.

Inconsistency on numbering Sampling point.

17.

Period 1-14 Oct 14, record of UV intensity meter is OOS (just reached 6%).
There is no documented DVR/investigation/similar adequate doc provided.
Request more info: need to investigate whether any RISK assessment in place in respect to product quality
since the UV is DIRECT impact CPP controlled device to eliminating Ozon

18.

Challenge test to control performance of AUTHOMATIC TLV Valve placed in production (user point) during
OZON process process is not in place
The related risk assessment in respect to any unperformed AUTHOMATIC TLV is not provided.
The qualification just done on annual basis. There is no guaranty for months before re-qualification

19.

Acceptance CRITERIA of Ozon concentration prior to be used by production has not established yet

20.

There is no record for ensuring of OZONE contacted time is not less than 3 hours as per required by SOP ENGUT/MSO/LS/009.
It is recommended to develop study for effective OZONE contacted time

Slide 126 of 25

2013

Water for Pharmaceutical Use


Group Session

21.

Sampling point no. 17 is not equipped by proper sampling valve, the position of sampling
point is not within looping system which represent PW looping condition

22.

Probe conductivity of multi steel water for producing WFI was not calibrated

23.

Recommendation:
The velocity of PW distribution is not in line with HAS and Local FDA requirements. 3000 liter/hours is
not enough for providing turbulence flow during distribution.
A risk assessment needs to be develop if the manufacturer still used their own spec

Water

Slide 127 of 25

2013

Water for Pharmaceutical Use


Group Session
2

The timing for introducing concentrated chlorination solution has not defined yet (SOP ENG UT/SOP/PM/030. This
condition has to describe chlorine concentration, initial tank condition before adding the concentrated chlorine in
respect to target dose since there is no testing of residual chlorine after treatment of chlorination itself

Daily monitoring of industrial RO unit is not equipped by acceptance criteria so that conclusion (pass/fail) of that monitoring
cannot be taken. It is important data for taking further improvement. This unit is belong Darmawans control

The usage of 20 microns filters can not be traced back since there is no documented link data due to details profile of used
filter such batch no, lot no, type and other related info since there is no testing of incoming filter, CoA is just used for filter
quality justification

1.
5

Water

2.

SOP ENG UT/SOP/PM/026, monitoring of DRW filter 20 microns filters, 12/1 2014 has 0,2 Pa while the acceptance
requirements is 0,3 pa
There is no appropriate column for describing P on before and after filtration (DRW) so that the operators calculate by
themselves without proper documentation. The record of individual filter is in place

Slide 128 of 25

2013

Water for Pharmaceutical Use


Group Session
6

There are no measurement devices to ensure the filtration performance of 1 filters. So on that reason, there is no
performance monitoring record of that particular filters
The frequency of filter changes are also not defined impacted by above reasons

There is no qualification label in PW generator unit.


It is suggested to perform re-qualification after usage of some period of time

Cold loop system:


UV intensity meter is not recorded, the same issue is also happen for UV working hours

10

Water

There is no in place technique to check the turbulence of PW inside of distribution piping. The appropriate flow meter is not in
place

Alert limit and action limit of conductivity are in place but the operator can change such water CQAs and CPPs without getting
authorization from related manager. Password management needs to re-change the password and re-training

Slide 129 of 25

2013

Water for Pharmaceutical Use


Group Session

Water

11

The cold loop report ENG- UT/FOR/PM/026 has not yet approved by QA but the PW itself has been distributed into
production area.
QA approved is required as per established SOP since this is CRITICAL step which needs quality people decision.
The related form has been established

12

Challenge test of main distribution valve after cold sanitation is not in place. There is no adequate system to ensure that the
valve is always working properly while its valve is not equipped by the periodic qualification.

13

Venting filters on storage tank:


The usage of 0,2 microns filters can not be traced back since there is no documented link data due to details profile of
used filter such batch no, lot no, type and other related info since there is no integrity testing of incoming filter, CoA is just
used for filter quality justification
The sequence activities for handling of filter change filters has considered cross contamination issues, but the SOP has not
up dated yet as per the actual handling

Slide 130 of 25

2013

Water for Pharmaceutical Use


Group Session

Water

14

The sequence of QC sampling time and PW distribution sanitation time is not representing worst case condition,
since it is only show the best case condition. QC sampling is in Tuesday while sanitation is Sunday

15

Ozone meter for checking residual ozone is not in place, but the operator use other system for ensuring there is not residual
ozone inside of PW. After ozonization, the PW is drained, but there is no record & evidence in place for ensuring that the PW
tank is empty before refill the new PW

Slide 131 of 25

2013

Water for Pharmaceutical Use


Group Session

Water

Slide 132 of 25

2013

Potrebbero piacerti anche